Lung cancer patients get new hope with Arginine-Starving drug combo

NCT ID NCT05616624

Terminated Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 28, 2026 · Updated 3 times

Summary

This study tests a three-drug combination (ADI-PEG 20, gemcitabine, and docetaxel) in people with lung cancer that has worsened after initial treatment. The goal is to find the safest dose and see if the combination can shrink tumors or slow disease progression. About 31 participants with non-small cell or small cell lung cancer will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ADI-PEG 20 (a drug that breaks down arginine, an amino acid cancer cells need) combined with gemcitabine and docetaxel (standard chemotherapy drugs)
What this could lead to: If successful, this could provide a new treatment option for lung cancer patients whose disease has worsened after initial therapy.
What could go wrong: This is an early-phase trial with only 31 participants, so results may not apply broadly. The combination may cause serious side effects, and it is unclear if it will improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER SMALL CELL LUNG CANCER SMALL CELL LUNG CARCINOMA

Contacts and locations

Locations

Inova Schar Cancer Institute

Fairfax, Virginia, 22031, United States
Northwestern University

Chicago, Illinois, 60611, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.